Alto Neuroscience, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANRO research report →
Companywww.altoneuroscience.com
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia.
- CEO
- Amit Etkin
- IPO
- 2024
- Employees
- 76
- HQ
- Mountain View, CA, US
Price Chart
Valuation
- Market Cap
- $721.88M
- P/E
- -9.11
- P/S
- 0.00
- P/B
- 2.78
- EV/EBITDA
- -6.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -47.22%
- ROIC
- 20.70%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-63,238,000 · -2.94%
- EPS
- $-2.19 · 12.40%
- Op Income
- $-66,364,000
- FCF YoY
- -4.63%
Performance & Tape
- 52W High
- $28.44
- 52W Low
- $2.15
- 50D MA
- $23.41
- 200D MA
- $14.55
- Beta
- 1.65
- Avg Volume
- 317.14K
Get TickerSpark's AI analysis on ANRO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Etkin Amit | other | 400,000 |
| May 12, 26 | Sanchez Ramiro | other | 10,958 |
| May 12, 26 | Cox Christopher Nixon | other | 10,958 |
| May 12, 26 | Manji Husseini | other | 10,958 |
| May 12, 26 | Dreyfus Andrew | other | 10,958 |
| May 12, 26 | York Gwill | other | 10,958 |
| Mar 1, 26 | Etkin Amit | other | 6,227 |
| Mar 1, 26 | Smith Nicholas Conrad | other | 2,806 |
| Feb 11, 26 | Etkin Amit | other | 306,000 |
| Feb 11, 26 | Savitz Adam | other | 124,000 |
Our ANRO Coverage
We haven't published any research on ANRO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANRO Report →